

Maartje J Hooning

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/843650/publications.pdf>

Version: 2024-02-01

114
papers

15,026
citations

47409

49
h-index

23841

115
g-index

117
all docs

117
docs citations

117
times ranked

20219
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. <i>Breast</i> , 2022, 61, 98-107.	0.9	6
2	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	2.2	15
3	Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study. <i>Breast Cancer Research and Treatment</i> , 2022, , .	1.1	1
4	Common Susceptibility Loci for Male Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 453-461.	3.0	12
5	Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 205-214.	1.1	19
6	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMONY Study). <i>JMIR Research Protocols</i> , 2021, 10, e24414.	0.5	9
7	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	2.9	5
8	Breast Cancer Risk Genes " Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	13.9	532
9	Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?. <i>Cancers</i> , 2021, 13, 2506.	1.7	17
10	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
11	Identification of Risk of Cardiovascular Disease by Automatic Quantification of Coronary Artery Calcifications on Radiotherapy Planning CT Scans in Patients With Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1024.	3.4	35
12	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	2.2	7
13	The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer. <i>Menopause</i> , 2021, Publish Ahead of Print, 1307-1312.	0.8	2
14	Effect of a health literacy training program for surgical oncologists and specialized nurses on disparities in referral to breast cancer genetic testing. <i>Breast</i> , 2021, 58, 80-87.	0.9	5
15	Heart failure after treatment for breast cancer. <i>European Journal of Heart Failure</i> , 2020, 22, 366-374.	2.9	28
16	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
17	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
18	Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. <i>JAMA Oncology</i> , 2020, 6, 1381.	3.4	31

#	ARTICLE	IF	CITATIONS
19	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	2.6	39
20	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 44.	2.3	5
21	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 60.	2.3	9
22	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
23	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	1.6	2
24	The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer. <i>Breast</i> , 2020, 52, 102-109.	0.9	2
25	Prognosis of acute coronary syndromes after radiotherapy for breast cancer. <i>Radiotherapy and Oncology</i> , 2020, 146, 110-117.	0.3	6
26	The impact of lifestyle and reproductive factors on the risk of a second new primary cancer in the contralateral breast: a systematic review and meta-analysis. <i>Cancer Causes and Control</i> , 2020, 31, 403-416.	0.8	20
27	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
28	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	5.8	30
29	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2020, 22, 8.	2.2	41
30	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 423-434.	1.1	14
31	The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 581-588.	1.1	10
32	Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 723-733.	1.1	111
33	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	1.6	5
34	MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 1136-1147.	5.1	112
35	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	2.9	52
36	Prediction and clinical utility of a contralateral breast cancer risk model. <i>Breast Cancer Research</i> , 2019, 21, 144.	2.2	24

#	ARTICLE	IF	CITATIONS
37	Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2019, 44, 1-14.	0.9	42
38	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	2.6	711
39	Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 1130-1139.	0.6	29
40	Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 595-604.	0.4	80
41	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. <i>International Journal of Cancer</i> , 2018, 143, 746-757.	2.3	19
42	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. <i>Scientific Reports</i> , 2018, 8, 6574.	1.6	51
43	Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 408-418.	2.9	50
44	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. <i>Nature Genetics</i> , 2017, 49, 834-841.	9.4	426
45	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2402.	3.8	1,898
46	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
47	Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 85, 31-38.	1.3	32
48	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
49	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
50	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	0.9	45
51	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2017, 8, 18381-18398.	0.8	14
52	<i>PHIP</i> - a novel candidate breast cancer susceptibility locus on 6q14.1. <i>Oncotarget</i> , 2017, 8, 102769-102782.	0.8	9
53	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. <i>Oncotarget</i> , 2016, 7, 80140-80163.	0.8	31
54	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. <i>PLoS Medicine</i> , 2016, 13, e1002105.	3.9	118

#	ARTICLE	IF	CITATIONS
55	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 1303-1317.	2.3	51
56	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
57	Recurrent <i>HOXB13</i> mutations in the Dutch population do not associate with increased breast cancer risk. <i>Scientific Reports</i> , 2016, 6, 30026.	1.6	3
58	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016, 27, 679-693.	0.8	21
59	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through <i>FGF10</i> and <i>MRPS30</i> Regulation. <i>American Journal of Human Genetics</i> , 2016, 99, 903-911.	2.6	59
60	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating <i>IGFBP5</i> expression. <i>Human Molecular Genetics</i> , 2016, 25, 3863-3876.	1.4	33
61	rs2735383, located at a microRNA binding site in the 3'UTR of <i>NBS1</i> , is not associated with breast cancer risk. <i>Scientific Reports</i> , 2016, 6, 36874.	1.6	2
62	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	7.7	157
63	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
64	Prognostic value of automated Ki67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. <i>Breast Cancer Research</i> , 2016, 18, 104.	2.2	56
65	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for <i>CH</i> <i>EK</i> <i>2</i> *1100delC Carriers. <i>Journal of Clinical Oncology</i> , 2016, 34, 2750-2760.	0.8	152
66	High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 138-153.	1.3	19
67	Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. <i>British Journal of Cancer</i> , 2016, 114, 631-637.	2.9	99
68	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. <i>Journal of Medical Genetics</i> , 2016, 53, 298-309.	1.5	94
69	Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
70	Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2016, 34, 409-418.	0.8	84
71	<i>RAD51B</i> in Familial Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0153788.	1.1	26
72	Improved overall survival after contralateral risk-reducing mastectomy in <i>BRCA1/2</i> mutation carriers with a history of unilateral breast cancer: A prospective analysis. <i>International Journal of Cancer</i> , 2015, 136, 668-677.	2.3	158

#	ARTICLE	IF	CITATIONS
73	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 978.	1.1	6
74	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	2.2	26
75	Survival benefit in women with <i>BRCA1</i> mutation or familial risk in the <i>MRI</i> screening study (<i>MRISC</i>). <i>International Journal of Cancer</i> , 2015, 137, 1729-1738.	2.3	78
76	SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. <i>Oncotarget</i> , 2015, 6, 37979-37994.	0.8	20
77	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	428
78	Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. <i>EBioMedicine</i> , 2015, 2, 681-689.	2.7	56
79	Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: A critical review of the literature. <i>Cancer Treatment Reviews</i> , 2015, 41, 187-196.	3.4	47
80	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015, 24, 2966-2984.	1.4	40
81	Tumor-associated inflammation as a potential prognostic tool in <i>BRCA1/2</i> -associated breast cancer. <i>Human Pathology</i> , 2015, 46, 182-190.	1.1	23
82	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	9.4	513
83	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate <i>NRBF2</i> Expression. <i>American Journal of Human Genetics</i> , 2015, 97, 22-34.	2.6	37
84	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	56
85	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and <i>BRCA1</i> -mediated DNA repair. <i>Nature Genetics</i> , 2015, 47, 1294-1303.	9.4	357
86	Adjuvant radiotherapy for primary breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 171-180.	1.1	32
87	<i>Annexin A1</i> expression in a pooled breast cancer series: association with tumor subtypes and prognosis. <i>BMC Medicine</i> , 2015, 13, 156.	2.3	51
88	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv219.	3.0	99
89	Identification and characterization of novel associations in the <i>CASP8/ALS2CR12</i> region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	1.4	38
90	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015, 6, 7390-7407.	0.8	15

#	ARTICLE	IF	CITATIONS
91	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	1.1	49
92	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	1.5	39
93	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. <i>Nature Communications</i> , 2014, 5, 4051.	5.8	16
94	Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy. <i>Cancer Biology and Therapy</i> , 2014, 15, 371-379.	1.5	6
95	Should we screen BRCA1 mutation carriers only with MRI? A multicenter study. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 577-582.	1.1	66
96	Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study. <i>International Journal of Cancer</i> , 2014, 135, 2940-2949.	2.3	13
97	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. <i>Nature</i> , 2014, 514, 92-97.	13.7	548
98	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	5.8	105
99	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014, 23, 6034-6046.	1.4	12
100	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	2.2	14
101	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013, 93, 1046-1060.	2.6	98
102	Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2013, 31, 3091-3099.	0.8	148
103	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
104	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. <i>American Journal of Human Genetics</i> , 2013, 92, 489-503.	2.6	201
105	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	9.4	374
106	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	9.4	960
107	Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1458-1468.	1.1	79
108	CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-Specific Death, and Increased Risk of a Second Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4308-4316.	0.8	162

#	ARTICLE	IF	CITATIONS
109	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012, 21, 3926-3939.	1.4	80
110	The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Cancer</i> , 2012, 118, 899-907.	2.0	83
111	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	1.4	152
112	<i>BRCA1</i> -Associated Breast Cancers Present Differently From <i>BRCA2</i> -Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5265-5273.	0.8	166
113	Roles of Radiotherapy and Chemotherapy in the Development of Contralateral Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5561-5568.	0.8	96
114	Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 365-375.	3.0	715